Armodafinil

NERVOUS SYSTEM

Key facts

Armodafinil is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 2007. DrugCentral lists 7 molecular targets, including DRD2, SLC6A3 and Slc6a3. Recorded indications include Narcolepsy, Sleepiness Due To Obstructive Sleep Apnea and Sleepiness Due To Shift Work Sleep Disorder.

• Approval status: ofp (first approved 2007 by the FDA).
• Molecular targets: DRD2, SLC6A3, Slc6a3 and DRD3 (7 listed in DrugCentral).
• Indications: Narcolepsy, Sleepiness Due To Obstructive Sleep Apnea and Sleepiness Due To Shift Work Sleep Disorder.
• ATC code: N06BA13 (Centrally acting sympathomimetics).
• Molecular formula: C15H15NO2S; molecular weight 273.35 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Narcolepsy
• Sleepiness Due To Obstructive Sleep Apnea
• Sleepiness Due To Shift Work Sleep Disorder

Contraindications (8)

• Depressive disorder
• Hepatic failure
• Hypertensive disorder
• Left ventricular hypertrophy
• Mania
• Mitral valve prolapse
• Psychotic disorder
• Suicidal thoughts

Mechanism & targets

Molecular targets (7)

Target	Gene	Action	Activity
D(2) dopamine receptor	DRD2	unknown	EC50 6.92
Sodium-dependent dopamine transporter	SLC6A3	inhibitor	IC50 5.50
Sodium-dependent dopamine transporter	Slc6a3	unknown	Ki 5.49
D(3) dopamine receptor	DRD3	unknown	Ki 4.41
Alpha-1B adrenergic receptor	ADRA1B	unknown	—
Cytochrome P450 1A2	CYP1A2	unknown	—
Cytochrome P450 2C19	CYP2C19	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2007-06-05	FDA	—	CEPHALON

ATC classification

ATC code	Therapeutic hierarchy
N06BA13	NERVOUS SYSTEM › PSYCHOANALEPTICS › PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS › Centrally acting sympathomimetics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Product administration interrupted	631.2
Pre-existing condition improved	410.6
Sleep apnoea syndrome	371.5
Anxiety	360.6
Suicidal ideation	297.5
Depression	282.3
Somnambulism	211.0
Surgery	172.7
Therapeutic response unexpected	172.4
Feeling abnormal	166.5
Somnolence	138.7
Feeling jittery	133.6

Chemical structure

• Molecular formula: C₁₅H₁₅NO₂S
• Molecular weight: 273.35 g/mol
• CAS number: 112111-43-0
• InChIKey: YFGHCGITMMYXAQ-LJQANCHMSA-N
• PubChem CID: 9690109

NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Armodafinil used for?

DrugCentral lists the following indications for Armodafinil: Narcolepsy, Sleepiness Due To Obstructive Sleep Apnea and Sleepiness Due To Shift Work Sleep Disorder.

How does Armodafinil work?

Its molecular targets in DrugCentral include DRD2, SLC6A3 (inhibitor), Slc6a3 and DRD3.

When was Armodafinil first approved?

Armodafinil was first approved by the FDA in 2007.

What is the chemical formula of Armodafinil?

Armodafinil has the molecular formula C15H15NO2S and a molecular weight of 273.35 g/mol.

Sources

• DrugCentral drug card 4501 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201192 — compound record and bioactivity
• PubChem CID 9690109 — chemical identifiers
• DrugBank DB06413 — drug record
• FDA UNII V63XWA605I — substance identity
• DailyMed: FDA labels for Armodafinil — current prescribing information (label search)
• UniProt P14416 (DRD2) — target protein
• UniProt Q01959 (SLC6A3) — target protein
• UniProt P35462 (DRD3) — target protein
• UniProt P35368 (ADRA1B) — target protein
• UniProt P05177 (CYP1A2) — target protein
• UniProt P33261 (CYP2C19) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.